Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
about
Aberrant expression of interleukin-1β and inflammasome activation in human malignant gliomasCurrent vaccine trials in glioblastoma: a reviewA short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiformeUnderstanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer TreatmentCurrent Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaNanoparticles for imaging and treating brain cancerEGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.Genetic signature of adult gliomas and correlation with MRI features.Immunocompetent murine models for the study of glioblastoma immunotherapyClinical applications of a peptide-based vaccine for glioblastoma.Development of an EGFRvIII specific recombinant antibodyAptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of gliomaEGFRvIII-targeted vaccination therapy of malignant glioma.Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma.Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapyA pan-cancer analysis of alternative splicing events reveals novel tumor-associated splice variants of matriptase.Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumoursThe role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cellsGlioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies.Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles.The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.Peptide-Targeted Gold Nanoparticles for Photodynamic Therapy of Brain Cancer.The value of EGFRvIII as the target for glioma vaccines.Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for gliomaGene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer modelEnhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma modelGlioma stem cells and immunotherapy for the treatment of malignant gliomas.Prioritization schema for immunotherapy clinical trials in glioblastoma.Targeted therapies for malignant glioma: progress and potential.Genetically engineered T cells to target EGFRvIII expressing glioblastoma.New strategies to deliver anticancer drugs to brain tumors.Design and development of therapies using chimeric antigen receptor-expressing T cells
P2860
Q24810414-74A8EBDB-6921-4A08-9EFA-C64FE8F4DAC1Q26828965-26E2AD2F-A355-4270-A673-48B13EFFB5CCQ26849375-33D00FD8-92A6-4201-8CAB-75B6E297C766Q27691330-7C02AFF4-4959-4339-8E69-186869BE0610Q28069424-0C153019-38B4-4AF1-9989-37BD263EB717Q28087306-468D0DEE-1C65-414E-9789-951F3FF0D21EQ28394053-10C7AB7D-0EE9-4C68-AB67-D392F7AE6A7CQ30456087-0018ECD3-5449-494E-B971-1B3731A90526Q33509600-33DA5345-1966-4068-BD53-FF2CE60C463EQ33574853-E5BDFB69-2EE6-48A4-8C54-9009EC3B24D7Q33668575-706013F6-CDD4-4E07-A119-D4DDDF5BCF00Q33711627-AD76A1CB-2568-4EF2-B051-8D4DAFB80E1AQ33734403-53168885-7D10-4034-994B-3457BEF1F3A0Q33758459-A6B79816-FCB7-484A-B83D-A0FE019E4122Q33923950-D1F1E093-6003-4229-A1C3-E2CB9F992894Q33945802-0C90EF8F-F779-43AF-B62E-B7736349AFFDQ33999299-20F747A9-2BCC-4F5C-9A1B-DF851F2C9912Q34496174-8DDA8EAF-8A96-480A-883B-9B8A81C5A465Q34655203-54B3C958-E3EC-4376-82C9-EBB389ACFFCEQ34744875-1554DE86-AB4D-47F6-9715-B940F8FA6DC0Q34902490-6C8D69E9-20A3-4BA4-9625-A2C238589AA4Q34950060-E1063492-E96D-4A92-992A-4C68DFA09BCDQ34971940-40E16D4B-AA77-4649-A02D-4CB6AF3CA3A4Q35000726-3409C670-51FC-4C98-A39C-D766AD6FF091Q35285859-2E79CC72-366E-429F-83FA-417DBB6B6C85Q35527165-53B8A553-F25A-4564-A110-81E9D19094D6Q35624110-B9ECF6FF-F860-4CFF-AD13-ED96D0E84B89Q35627573-4D5BB32F-1CDC-4816-9198-C9C7C981B554Q35914541-1E4E6643-D77E-4117-880B-F7D1B962D1FFQ35999648-4C6C0B2B-4279-43CA-A76C-3CD91C75C25EQ36280796-4323FFE6-2E21-4FF6-BE67-FF98AB35EE65Q36321176-4EB96690-8549-4CFE-9A65-8D39BB4BB981Q36345439-8D085EA3-173A-49D8-AC88-C60C0242F4DEQ36494531-68318FE6-E41A-46D9-A6DF-415A37971C6DQ36898699-76942D3B-C1DB-4A41-9608-A1A475D7D969Q37078999-CB7AAC76-399F-42D5-A458-74640B710098Q37159549-23238098-CE8A-426B-95DC-0E2C639DC42DQ37316117-98B7C8EA-BBB3-441A-BD42-1F0F7E23C76EQ37364700-B626AAB7-B569-46D0-B522-FF1DC343A774Q37418289-F2F47C00-5207-4AC3-BD0F-56F5CC49BA74
P2860
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor-specific immunotherapy t ...... atients with malignant glioma.
@en
Tumor-specific immunotherapy t ...... atients with malignant glioma.
@nl
type
label
Tumor-specific immunotherapy t ...... atients with malignant glioma.
@en
Tumor-specific immunotherapy t ...... atients with malignant glioma.
@nl
prefLabel
Tumor-specific immunotherapy t ...... atients with malignant glioma.
@en
Tumor-specific immunotherapy t ...... atients with malignant glioma.
@nl
P2093
P2860
P1476
Tumor-specific immunotherapy t ...... atients with malignant glioma.
@en
P2093
Amy B Heimberger
Duane A Mitchell
Gary E Archer
John H Sampson
P2860
P304
P356
10.1016/J.SMIM.2008.04.001
P577
2008-06-09T00:00:00Z